Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). by Ayana Ablayeva (22103708)

Subjects:

Initial participants by wave*. by Yeo Ju Sohn (18536198)

Subjects:

General characteristics of research participants. by Yeo Ju Sohn (18536198)

Subjects:

Absolute and relative cardiomyopathy and myocarditis DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative overall CVD DALYs rate attributable to 2^nd-level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative aortic aneurysm DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative overall CVD DALYs rate attributable to 1^st-level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…(<b>C</b>) Y-27632 collaborated with BA to alleviate the decrease in FD-4 flux in LPS-induced Caco2 cells on day 22. …”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Effects of GJE extract treatment decreased protein expression of MMP-12, α-SMA, IL-13, and TGF-β1 levels. by Natnicha Suttawong (22367172)

Risk of ischemic stroke according to the use of each anti-rheumatic agents. by Soo Min Ahn (10333246)

Subjects:

Tax1bp1-deficiency decreases the frequency of microabscess formation and lymphocyte depletion during <i>L. monocytogenes</i> infection. by Jeffrey Chin (22538086)